Pharmacodynamic Study Using FLT-PET/CT in Patients With Advanced Solid Malignancies Treated With a Sequential Combination of X-82 and Docetaxel
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Docetaxel (Primary) ; Vorolanib (Primary) ; F-18 fluorothymidine
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
- 04 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2017.